ARQT
Arcutis Biotherapeutics Inc
25.20$
-0.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 37.1% | 16.4% | 28.2% | 15.0% | 3.1% | 16.6% | 6.6% | 11.2% | 12.3% | 9.7% | 13.4% | 9.2% | 8.8% | 9.0% | 9.3% | 8.4% | 8.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 62.9% | 83.6% | 71.8% | 85.0% | 96.9% | 83.4% | 93.4% | 88.8% | 87.7% | 90.3% | 86.6% | 90.8% | 91.2% | 91.0% | 90.7% | 91.6% | 91.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 9,618.1% | 1,144.1% | 1,270.9% | 485.9% | 68.8% | 175.8% | 46.7% | 62.5% | 43.6% | 20.3% | 26.6% | 23.9% | 19.8% | 15.8% | 29.1% | 15.7% | 19.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 4,892.8% | 1,676.1% | 208.2% | 885.5% | 124.9% | 1,009.0% | 110.5% | 188.5% | 131.4% | 80.7% | 97.2% | 84.9% | 62.9% | 61.0% | 70.3% | 63.3% | 64.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 14,510.9% | 2,394.5% | 2,814.2% | 1,371.4% | 193.7% | 535.6% | 157.2% | 251.1% | 175.0% | 101.0% | 123.8% | 108.7% | 82.7% | 76.8% | 99.3% | 78.9% | 83.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -14,448.0% | -2,310.8% | -2,742.4% | -1,286.4% | -96.8% | -452.2% | -63.8% | -162.3% | -87.3% | -10.7% | -37.3% | -17.9% | 8.6% | 14.2% | -8.6% | 12.7% | 7.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 675.7% | 233.5% | 253.2% | 141.6% | 19.8% | 57.4% | 15.1% | 24.3% | 14.9% | 7.8% | 4.5% | 3.7% | 3.1% | 2.3% | 4.1% | 2.6% | 3.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -14,856.4% | -2,432.3% | -2,880.3% | -1,367.8% | -109.5% | -489.9% | -70.7% | -169.6% | -92.8% | -14.7% | -37.6% | -19.1% | 7.5% | 13.8% | -10.6% | 11.7% | 6.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 408.4% | 121.4% | -13.1% | 194.3% | 7.9% | 0.2% | 0.7% | 1.0% | – | 0.5% | 0.4% | 0.4% | 0.1% | 0.4% | 0.1% | 0.1% | 0.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -14,856.4% | -2,432.3% | -2,867.2% | -1,367.8% | -117.5% | -490.0% | -71.4% | -169.6% | -92.8% | -15.1% | -38.1% | -19.5% | 7.5% | 13.4% | -10.7% | 11.6% | 6.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -14,148.1% | -2,187.0% | -2,614.0% | -1,218.8% | -88.7% | -429.6% | -54.9% | -144.2% | -74.7% | -6.2% | -28.3% | -14.7% | 11.2% | 17.1% | -6.0% | 13.2% | 9.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.